RUFLOXACIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H18FN3O3S
Molecular Weight	363.407
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CCN(CC1)C2=C3SCCN4C=C(C(O)=O)C(=O)C(C=C2F)=C34

InChI

InChIKey=NJCJBUHJQLFDSW-UHFFFAOYSA-N

InChI=1S/C17H18FN3O3S/c1-19-2-4-20(5-3-19)14-12(18)8-10-13-16(14)25-7-6-21(13)9-11(15(10)22)17(23)24/h8-9H,2-7H2,1H3,(H,23,24)

HIDE SMILES / InChI

Molecular Formula	C17H18FN3O3S
Molecular Weight	363.407
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.torrinomedica.it/schede-farmaci/tebraxin_-_tebraxin_150/ | https://www.ncbi.nlm.nih.gov/pubmed/2743869 | https://www.ncbi.nlm.nih.gov/pubmed/1653205

Rufloxacin (MF-934) is a fluoroquinolone antibacterial drug. It acts as a DNA gyrase inhibitor. Rufloxacin shows in vitro antibacterial activity against E. coli, Salmonella, Klebsiella, Proteus and Staphylococcus spp. Lower in vitro activity was observed with Pseudomonas, Serratia, Enterobacter and the streptococci group D. Rufloxacin is indicated for the treatment of lower respiratory tract and urinary tract infections caused by germs sensitive to rufloxacin.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial DNA gyrase 66 Target ID: CHEMBL2311224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1653205 \| https://www.ncbi.nlm.nih.gov/pubmed/9372430	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Lower respiratory tract infection 2 Sources: https://www.torrinomedica.it/schede-farmaci/tebraxin_-_tebraxin_150/
Urinary tract infections 207 Sources: https://www.torrinomedica.it/schede-farmaci/tebraxin_-_tebraxin_150/https://www.torrinomedica.it/schede-farmaci/tebraxin_-_tebraxin_150/

PubMed

Title	Date	PubMed
6-Aminoquinolones as new potential anti-HIV agents.	2000-10-05	11020296
Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.	2000-10	10991859
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.	2000-10	10991858
Effects of some quinolones on imipenem-induced seizures in DBA/2 mice.	1994-03	8026738
The in-vitro activity of two new quinolones: rufloxacin and MF 961.	1992-06	1324239

Sample Use Guides

In Vivo Use Guide

The recommended dosage is 2 Tebraxin tablets (rufloxacin hydrochloride 150 or 200 mg) taken together the first day and one tablet per day in the following days. The duration of the treatment must be adapted to the severity of the case as well as to the clinical and bacteriological course; generally, 5 to 10 days of therapy are sufficient.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:15:46 GMT 2025` Edited by `admin` on `Mon Mar 31 18:15:46 GMT 2025`
Record UNII	Y521XM2900
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MF 934

Preferred Name

English

RUFLOXACIN

Official Name

English

NSC-759835

Code

English

RUFLOXACIN [MI]

Common Name

English

Rufloxacin [WHO-DD]

Common Name

English

rufloxacin [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C795